FASLG and Fulminant hepatitis: This ligand-independent activation of Fas/CD95 has a great potential therapeutic utility as it avoids the toxic side effects derived from the use of FasL/CD95L and agonistic anti-Fas/CD95 antibodies in vivo, that lead to a fatal hepatic damage with symptoms similar to fulminant hepatitis [9], [10].